Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,743 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gastrointestinal Symptoms Clear all

Conditions: HIV, Hepatitis C
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Liver Diseases, Healthy, Cirrhosis, Liver, Fibrosis
Interventions: Group K Diagnostic point of care device; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm, Malignant Ovarian Neoplasm, Malignant Pelvic Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm, Malignant Vaginal Neoplasm, Malignant Vulvar Neoplasm, Rectal Carcinoma
Interventions: Explantation, Quality-of-Life Assessment, Questionnaire Administration, Sacral Nerve Stimulator, Sacral Nerve Stimulator Battery, Therapeutic Conventional Surgery; Procedure · Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Houston, Texas • Sugar Land, Texas

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more

Conditions: Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
Interventions: Mindfulness Based Stress Reduction (MBSR); Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Ileus
Interventions: chewing gum - Extra Winterfresh, Standard Post-Op Care; Other
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Parkinson's Disease, Dysphagia, Dystussia
Interventions: EMST, smTAP; Device · Behavioral
Lead sponsor: Teachers College, Columbia University; Other
Eligibility: 45 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 7
States / cities: Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more

Conditions: Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm
Interventions: Carfilzomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Postoperative Ileus, Colon Cancer, Pain, Postoperative, Postoperative Nausea and Vomiting
Interventions: Acupuncture, Sham Acupuncture; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst, Family History of Pancreas Cancer, Genetic Mutations
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 1,368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 2
States / cities: New York, New York

Conditions: Cachexia, Weight Loss, Gastrointestinal Cancer
Interventions: EXCAP©®; Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cancer
Interventions: ziv-aflibercept; Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Acute Appendicitis, Abscess
Interventions: Normal Saline, Sterile Water; Procedure
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 6 Years and older
Enrollment: 241 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Metastatic Gastric Cancer, Locally Advanced Gastric Cancer
Interventions: Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly; Drug
Lead sponsor: Huashan Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)
Interventions: ALX2004; Drug
Lead sponsor: ALX Oncology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: La Jolla, California • Santa Monica, California • Tampa, Florida + 9 more

Conditions: Neoplasm Metastasis, Colorectal Neoplasms
Interventions: Celecoxib, Irinotecan, 5-fluorouracil, Leucovorin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 12
States / cities: Mobile, Alabama • Fort Lauderdale, Florida • Port Saint Lucie, Florida + 9 more

Conditions: End Stage Renal Disease, Chronic Hepatitis c
Interventions: Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 34 Years to 44 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liver Cirrhosis
Interventions: Zibotentan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions: Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim; Drug · Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 39 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Acid Reflux Disease, Heartburn
Interventions: Cell~vizio (Laser connfocal microscopy); Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pelvic Organ Prolapse, Cystocele, Rectocele, Enterocele
Interventions: Robotic sacrocolpopexy, high uterosacral ligament suspension; Procedure
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: NAFLD, NASH
Interventions: LiverFASt; Diagnostic Test
Lead sponsor: Fibronostics USA, Inc; Other
Eligibility: 18 Years to 80 Years
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 30 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects

Validation of Point of Care Liver Function Tests

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease

Prevention of Ileus After Gynecologic Surgery Using Chewing Gum

Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

Trial of Acupuncture for Reduction of Post-Colectomy Ileus

Pancreas Registry and High Risk Registry

The Effects of a 12 Week Home-based Exercise Intervention on Physical Performance in Patients With Cancers of the Gastrointestinal Tract With Pre- Cachexia or Cachexia

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Water And Saline Head-to-head In The Blinded Evaluation Study Trial

Metronomic Chemotherapy in Advanced Gastric Cancer

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Confocal Laser Microscopy in Non Erosive Reflux Disease

SCP vs HUSLS for Pelvic Organ Prolapse Repair

Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy

Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis